Five-year recurrence rates for women with ductal carcinoma in situ have been cut in half recently due to advances in mammography and more detailed pathology assessments.
Mark L. Fuerst
Adjuvant radiation therapy after lumpectomy improves survival for elderly women with early-stage, triple-negative breast cancer, according to a study to be presented at the 2015 ASCO Breast Cancer Symposium.
Nicotinamide may lower the incidence of new nonmelanoma skin cancers in patients at high risk for skin cancer, providing a new chemopreventive opportunity.
Whole brain radiation therapy helps control tumor growth in patients with 1 to 3 small brain metastases, but it does not significantly extend patient survival.
A combination of lenvatinib plus everolimus improved survival and overall response compared with everolimus alone in metastatic renal cell carcinoma patients.
Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.
Advanced bladder cancer patients with poor prognosis appear to benefit from adding apatorsen 600 mg to first-line chemotherapy with gemcitabine/cisplatin.
Pembrolizumab demonstrates durable antitumor activity in patients with advanced urothelial cancer, with a higher response rate seen in patients with PD-L1 expression.
The addition of bevacizumab to carboplatin/paclitaxel chemotherapy increases progression-free survival in advanced/recurrent endometrial cancer patients.
Treating advanced sarcoma with the chemotherapy agent eribulin improves overall survival compared with treatment with standard therapy with dacarbazine.